Ocular Therapeutix (OCUL) Work In Process (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Work In Process of $1.1 million for Q2 2026, down 35.25% year-over-year from $1.7 million in Q2 2025, and down 9.5% on a QoQ basis from $1.2 million in Q1 2026.
Ocular Therapeutix (OCUL) Work In Process (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported Work In Process for 13 years, with the latest figure at $1.1 million in Q2 2026.
- Work In Process for Q2 2026 came in at $1.1 million, down 35.25% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.1 million (down 35.25% YoY), and the FY2025 annual result was $1.7 million, up 15.58% from the prior year.
- Work In Process fell to $1.1 million in Q2 2026, from $1.2 million in the prior quarter.
- Over five years, Work In Process peaked at $1.8 million in Q1 2025 and troughed at $567000.0 in Q1 2022.
- A 5-year average of $1.1 million and a median of $1.0 million in 2023 frame the typical range for Work In Process.
- The widest annual swing landed in 2025, when Work In Process jumped 97.27%; it then slumped 35.25% in 2026.
- A 5-year view of Work In Process shows it stood at $899000.0 in 2022, then advanced by 12.57% to $1.0 million in 2023, then jumped by 47.13% to $1.5 million in 2024, then grew by 15.58% to $1.7 million in 2025, then tumbled by 34.69% to $1.1 million in 2026.
- Per Business Quant data, the three most recent Work In Process figures were $1.1 million in Q2 2026, $1.2 million in Q1 2026, and $1.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Mn |
| Mar 31, 2026 | 1.24 Mn |
| Dec 31, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.81 Mn |
| Dec 31, 2024 | 1.49 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.06 Mn |
| Mar 31, 2024 | 915,000.00 |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 947,000.00 |
| Jun 30, 2023 | 682,000.00 |
| Mar 31, 2023 | 773,000.00 |
| Dec 31, 2022 | 899,000.00 |
| Sep 30, 2022 | 885,000.00 |
| Jun 30, 2022 | 662,000.00 |
| Mar 31, 2022 | 567,000.00 |
| Dec 31, 2021 | 605,000.00 |
| Sep 30, 2021 | 563,000.00 |